These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35178466)

  • 1. Estimating Potential for Drug Budget Reallocation Following Expiration of Exclusivity of Pharmaceutical Products.
    Toghanian S; Moshtaghi-Svensson J; Papageorgiou M; Kittelsen K; Dolk C; Hultstrand M; Salomonsson S
    J Health Econ Outcomes Res; 2022; 9(1):20-30. PubMed ID: 35178466
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility.
    Lee SM; Kim HJ; Suh D; Joung KI; Kim ES; Back HJ; Kwon JY; Park MJ; Suh DC
    BMC Health Serv Res; 2021 Feb; 21(1):126. PubMed ID: 33549099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EU pharmaceutical expenditure forecast.
    Urbinati D; Rémuzat C; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
    J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical expenditure forecast model to support health policy decision making.
    Rémuzat C; Urbinati D; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
    J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Hua LH; Hersh CM; Morten P; Kusel J; Lin F; Cave J; Varga S; Herrera V; Ko JJ
    J Manag Care Spec Pharm; 2019 Apr; 25(4):490-498. PubMed ID: 30917079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.
    García-Goñi M; Río-Álvarez I; Carcedo D; Villacampa A
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33918795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel methodology for pharmaceutical expenditure forecast.
    Vataire AL; Cetinsoy L; Aballéa S; Rémuzat C; Urbinati D; Kornfeld Å; Mzoughi O; Toumi M
    J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
    Hutchings A; Schey C; Dutton R; Achana F; Antonov K
    Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel.
    Kanters TA; Stevanovic J; Huys I; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():322. PubMed ID: 28620302
    [No Abstract]   [Full Text] [Related]  

  • 11. Patent Cliffs in the Era of Complex Therapies and Biologics.
    Sabatini MT; Silva M
    Pharmaceut Med; 2020 Aug; 34(4):271-278. PubMed ID: 32772314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Expiry of Humira
    Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
    Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
    [No Abstract]   [Full Text] [Related]  

  • 13. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 14. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
    Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
    Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Market diffusion of biosimilars in off-patent biologic drug markets across Europe.
    Böhm AK; Steiner IM; Stargardt T
    Health Policy; 2023 Jun; 132():104818. PubMed ID: 37086662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
    Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
    Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
    Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.
    Trautman H; Szabo E; James E; Tang B
    J Manag Care Spec Pharm; 2019 Jan; 25(1):94-101. PubMed ID: 30084301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
    Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
    Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.